New diabetes drug aims to match top pill in head-to-head trial
NCT ID NCT07487103
First seen Apr 21, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This study compares a new medicine called QLG1091 to an existing drug, Rybelsus, in people with type 2 diabetes who already take metformin. About 478 adults will receive either QLG1091 or Rybelsus for 26 weeks to see if the new drug works just as well at lowering blood sugar. The goal is to control diabetes, not cure it, and participants will need to keep managing their condition long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.